Stocktoria
TherapeuticsMD, Inc. TXMD
TherapeuticsMD, Inc. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.0M | $1.8M | $1.3M | $70.0M | $2.6M | $64.9M | $49.6M | $16.1M | $16.8M | $19.4M |
| Gross profit | — | — | $1.3M | $68.6M | $1.2M | $48.9M | $43.3M | $13.4M | $14.1M | $15.2M |
| R&D expense | — | — | — | — | $7.1M | $10.4M | $19.8M | $27.3M | $33.9M | $53.9M |
| SG&A expense | — | $4.7M | $8.9M | — | — | $193.0M | $174.1M | $116.0M | $57.7M | $51.3M |
| Operating income | -$4.4M | -$6.1M | -$8.5M | $1.2M | -$79.6M | -$155.5M | -$151.2M | -$130.2M | -$77.6M | -$90.3M |
| Interest expense | — | — | $300,000 | $200,000 | $32.9M | $28.6M | $17.4M | $4.7M | — | — |
| Income tax | — | -$31,000 | -$43,000 | — | — | — | — | — | — | — |
| Net income | -$569,000 | -$2.2M | -$10.3M | $112.0M | -$172.4M | -$183.5M | -$176.1M | -$132.6M | -$76.9M | -$89.9M |
| EPS (diluted) | $-0.05 | $-0.19 | $-0.99 | $11.96 | $-21.66 | — | — | — | — | — |
| Operating cash flow | $2.5M | $1.2M | -$23.1M | $9.4M | -$142.7M | -$159.5M | -$165.7M | -$106.8M | -$76.2M | -$69.1M |
| Free cash flow | — | — | — | — | -$142.7M | -$159.7M | -$168.2M | -$107.0M | -$76.2M | -$69.5M |
| Cash & equivalents | — | $5.1M | $4.3M | — | — | — | — | — | — | — |
| Inventory | — | — | — | — | $7.6M | $8.0M | $11.9M | $3.3M | $1.5M | $1.1M |
| Total assets | $37.7M | $38.8M | $43.3M | $90.5M | $169.5M | $181.6M | $266.0M | $212.0M | $143.2M | $142.5M |
| Total liabilities | $10.8M | $11.5M | $14.0M | $55.3M | $263.1M | $305.6M | $256.8M | $114.5M | $13.3M | — |
| Shareholders' equity | $26.9M | $27.4M | $29.3M | $35.1M | -$93.6M | -$124.0M | $9.2M | $97.5M | $129.9M | $127.5M |
Growth · year-over-year · Revenue CAGR -18.6%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +71.6% | +35.3% | -98.1% | +2619.1% | -96.0% | +30.7% | +208.4% | -4.0% | -13.3% | -3.9% |
| Net income growth | — | — | -109.2% | — | — | — | — | — | — | — |
| EPS growth | — | — | -108.3% | — | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.